Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tcr2 Therapeutics Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The current prosecution is handled by a distinct examiner and a distinct art unit, representing a narrow scope of activity.
SKELDING, ZACHARY S is the busiest examiner, responsible for 1 pending office action. This examiner oversees the total pending volume, which focuses the company's current interactions with the patent office in the identified art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269214 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269214 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | SKELDING, ZACHARY S | 1644 | §103Other | Non-Final OA | — | Pending | Jun 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTcr2 Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Zachary S Skelding has the most, with 1 of Tcr2 Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.